

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



14th August, 2018

To
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

To,
**National Stock Exchange of India
Limited**
“Exchange Plaza”,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051

Scrp Code: 532637

Symbol: MANGALAM

Re: Press Release – Un-audited Financial Results for Quarter ended 30th June, 2018

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the company has hereby issued a Press Release mentioned below on the aforesaid subject:

The anti-malaria market is generally down in the first quarter, due to which the turnover has dropped from Rs. 6729.76 lacs in March 2018 to Rs. 5903.48 lacs in June, 2018. However if compared to June 2017 turnover of Rs. 5518.06 lacs it has increased by almost 7%.

The profitability is low since the exchange rate has adversely gone down and the change in selling price to customers is yet to be affected.

We request you to take on record the aforesaid information.

Thanking You,

Yours Faithfully,
For **Mangalam Drugs & Organics Ltd**

Govardhan M Dhoot
Managing Director
DIN: 01240086



Works: at Vapi (Gujarat) India • E-Mail : contactus@mangalamdrugs.com • Website : <http://www.mangalamdrugs.com>